A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in β-thalassaemia patients with transfusional haemosiderosis
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Keyword(s):
2015 ◽
Vol 23
(3)
◽
pp. S170-S171
◽
Keyword(s):